Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Mental Health

Date Submitted: Mar 13, 2025
Date Accepted: Aug 16, 2025

The final, peer-reviewed published version of this preprint can be found here:

Group Cognitive Behavioral Therapy With Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia: Underpowered Results From the SoREAL Pragmatic Randomized Clinical Trial

Arnfred B, Zeka F, Hjorthøj C, Christensen CW, Moeller KS, Øllgaard MP, Rosenberg N, Clemmensen L, Glenthøj LB, Nordentoft M

Group Cognitive Behavioral Therapy With Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia: Underpowered Results From the SoREAL Pragmatic Randomized Clinical Trial

JMIR Ment Health 2025;12:e73815

DOI: 10.2196/73815

PMID: 41183277

PMCID: 12582524

Underpowered results from the SoREAL Pragmatic Randomized Clinical Trial: Group Cognitive Behavioral Therapy with Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia

  • Benjamin Arnfred; 
  • Fatime Zeka; 
  • Carsten Hjorthøj; 
  • Clas Winding Christensen; 
  • Kirsten Stengaard Moeller; 
  • Mette Pedersen Øllgaard; 
  • Nicole Rosenberg; 
  • Lars Clemmensen; 
  • Louise Birkedal Glenthøj; 
  • Merete Nordentoft

ABSTRACT

Background:

Social anxiety disorder (SAD) and agoraphobia are common, impairing conditions often treated with cognitive behavioral therapy (CBT), in which exposure therapy is a core element. Virtual reality exposure (VRE) has shown promise as a flexible alternative to in-vivo exposure.

Objective:

This trial evaluated the efficacy of group CBT with VRE (VR-CBT) versus CBT with in-vivo exposure for treating SAD and agoraphobia in clinical settings.

Methods:

In this randomized, parallel-group, assessor-blinded trial, 177 participants with SAD or agoraphobia were assigned to either VR-CBT or traditional CBT across five Danish mental health outpatient clinics. Both groups received 14 weekly group sessions. Primary outcomes were phobic anxiety reductions, measured by the Liebowitz Social Anxiety Scale (LSAS) and the Mobility Inventory for Agoraphobia (MIA). Secondary outcomes included work and social functioning, depressive symptoms, and quality of life.

Results:

Both groups showed significant reductions in primary, secondary, and exploratory outcomes, with no significant differences between groups. Baseline characteristics and attrition rates were balanced across groups.

Conclusions:

Due to insufficient recruitment and substantial missing data, no definitive conclusions can be drawn regarding group differences between VR-CBT and traditional CBT in group settings. The feasibility issues encountered suggest that careful consideration of the benefits and limitations of VR technology is essential before implementation in clinical practice. Clinical Trial: NCT03845101


 Citation

Please cite as:

Arnfred B, Zeka F, Hjorthøj C, Christensen CW, Moeller KS, Øllgaard MP, Rosenberg N, Clemmensen L, Glenthøj LB, Nordentoft M

Group Cognitive Behavioral Therapy With Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia: Underpowered Results From the SoREAL Pragmatic Randomized Clinical Trial

JMIR Ment Health 2025;12:e73815

DOI: 10.2196/73815

PMID: 41183277

PMCID: 12582524

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.